Pegcetacoplan vs. Avacincaptad Pegol in Patients with GA: An Anchored MAIC of O&D vs. GATHER2
Access Resources

Identifying patients most benefitting from pegcetacoplan by AI-guided assessment of retinal pigment epithelium (RPE) and photoreceptor (PR) integrity in geographic atrophy (GA) secondary to age-related macular degeneration (AMD)​
Access Resources

Efficacy and Safety of Pegcetacoplan in Patients with Geographic Atrophy from the Phase 3 OAKS and DERBY trials with Efficacy Data from GALE
Access Resources

Pegcetacoplan therapy in geographic atrophy (GA): Therapeutic effects on retinal pigment epithelium (RPE) and photoreceptor (PR) integrity and function in the phase III clinical trials
Access Resources

Importance of automated OCT analysis for the longitudinal monitoring of geographic atrophy in clinical trials and the real-world
Access Resources

Pegcetacoplan treatment prolongs foveal sensitivity and light perception in the foveal center of patients with Geographic Atrophy (GA) as measured in the Phase 3 OAKS study
Access Resources

Retinal Tissue Preservation with Intravitreal Pegcetacoplan in Patients with Geographic Atrophy from the Phase 3 OAKS and DERBY trials
Access Resources

Projected 5-year Modelling of Lesion Growth Delay with Pegcetacoplan Based on Data from the OAKS and DERBY Trials in Patients with Geographic Atrophy
Access Resources

Assessment of Visual Function Changes on Microperimetry in High-Risk Areas of the Retina in Patients with Geographic Atrophy from the Phase 3 OAKS Trial
Access Resources

The MOSAIC Study: A clinical, humanistic, and economic burden of illness study among patients with geographic atrophy (GA) and their caregivers in Europe
Access Resources

Characterization of Exudative Age-Related Macular Degeneration from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Access Resources